Impact of parietal cell autoantibodies and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis C virus infection: A pilot study

Nikolaos K. Gatselis, Sarah P. Georgiadou, Nikolaos Tassopoulos, Kalliopi Zachou, Christos Liaskos, Angelos Hatzakis, Georgios N. Dalekos

Abstract

AIM: Various side effects have been reported in patients infected with hepatitis C virus (HCV) who were treated with interferon-alpha (IFN-α), including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA). However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α, and the impact of these autoantibodies on the treatment outcome of HCV patients.

METHODS: We investigated whether parietal cell autoantibodies (PCA) and/or NOSA were related with virological and biochemical sustained virological response and furthermore, to address which was, if any, their impact on the treatment outcome of patients with hepatitis C virus infection. A pilot study. World J Gastroenterol 2005; 11(4): 482-487

INTRODUCTION

Hepatitis C virus (HCV) infection has been associated with several immune-mediated phenomena including autoimmune thyroiditis[1], Sjogren’s-like syndrome[2], essential mixed cryoglobulinemia[3], and autoantibody production[4-16]. Administration of interferon-alpha (IFN-α) in combination with ribavirin has already been proved to be the most promising therapeutic approach for the treatment of HCV infection[17-19]. Various side-effects have been reported in patients treated with this cytokine, including the appearance or exacerbation of underlying autoimmune diseases and the development of a variety of organ and non-organ specific autoantibodies (NOSA)[14,23-28]. However, very few studies in adults have been strictly designed to address: whether the prevalence and the titre of organ and NOSA in serial samples of HCV-treated patients were affected by IFN-α therapy, and the impact of these autoantibodies on the treatment outcome of HCV patients[23-28].

We conducted a retrospective serological study in order to evaluate at three time-points (entry, end of treatment, end of follow-up) whether parietal cell autoantibodies (PCA) and NOSA in HCV-treated patients were affected by the IFN-α treatment and furthermore, to address which was, if any, their impact on the treatment outcome. We report here our first results.

MATERIALS AND METHODS

Patients

Sera from 57 selected HCV patients, previously treated with a course of antiviral therapy, were studied. According to the aim of the study, serum samples were collected at three time-points: baseline, end of treatment and end of follow-up (6-12 mo after suspension of therapy). In order to address our hypothesis, these samples were selected from our records in an attempt to make three groups of HCV patients matched for age, sex, HCV-genotype and HCV viral load. The first group was consisted of 19 patients who achieved combined sustained virological and...
biochemical response (responders), the second of 16 who had relapsed after an initial response at the end of treatment (relapsers) and the third of 22 who had no response (non-responders). At the end of treatment, biochemical response was achieved in 46 patients (81%), virological response in 37 (65%) and combined biochemical and virological response in 35 (61%).

At the end of follow up, sustained biochemical response was observed in 33 patients (58%), sustained virological response in 20 (35%) and combined sustained biochemical and virological response in 19 (33%).

Diagnosis of HCV infection was based on clinical, laboratory and histological evaluations as we described previously. All patients had no clinical laboratory or histological signs of autoimmune hepatitis (revised score for the diagnosis of this disease was less than 10 in all of them). Twenty-seven patients were treated with IFN-α (3 MU three times weekly) and ribavirin (19 patients infected with genotype 1 or 4 and two patients with undetermined genotype received 1 000-1 200 mg ribavirin daily, while 6 patients with genotype 2 or 3 received 800 mg/d) for 48 wk. The remaining 30 patients received IFN-α only (3 MU three times weekly) for 24-48 wk. Patients were followed up at least for 18 mo from the beginning of treatment.

Patients were regularly seen in the outpatient clinic for physical examination, blood tests and virological assays. Serum samples of the patients were investigated at the three time-points for PCA and NOSA. A complete medical history, routine liver function tests, virological tests and histological evaluation were also available.

The end-of-treatment and end-of-follow-up responses were defined as the normalization of serum alanine aminotransferase level (ALT) at the end of treatment and follow-up period (biochemical response) and as the clearance of serum HCV-RNA by polymerase chain reaction (PCR) at the same time-points (virological response).

**Histology**

Liver biopsy specimens were available in 35 cases before the initiation of therapy. Nineteen HCV-infected patients with genotype 2 or 3 were excluded from biopsy, because of the favorable response to treatment and 3 patients were denied. The histological evaluation was assessed using the Knodell histologic/activity index score. The inflammation score was obtained by combining the scores for the first three components of the Knodell index: portal, periportal and lobular inflammation (range 0-18). The Knodell fibrosis scores were: 0 (no fibrosis), 1 (portal fibrosis), 2 (portal fibrosis with few septa), 3 (bridging fibrosis) and 4 (cirrhosis). According to the previous publications of our group, patients were divided in to two groups according to inflammation: minimal/mild (0-8) and moderate/severe (9-18) and fibrosis none/mild/moderate (0-2) and severe fibrosis/cirrhosis (3-4).

**Virologic tests**

Serologic evidence of HCV infection was determined by the detection of antibodies to HCV (anti-HCV) using a third generation enzyme immunoassay (Murex Diagnostics, Temple Hill, Dartford, UK). HCV-RNA levels were available in all patients using a commercially quantitative PCR (Cobas Amplicor HCV Monitor, Roche). HCV genotypes were determined by a reverse-hybridization method (InnoLipa HCV II, Innogenetics). Classification of genotypes was done according to Simmonds et al. None of the patients studied was positive for hepatitis B surface antigen and antibodies to human immunodeficiency virus.

**Detection of autoantibodies**

Serum samples were tested for PCA and NOSA by two independent observers (N.G and G.D) blindly to the clinical status and the treatment outcome of the patients (double blind study).

Antinuclear antibodies (ANA) were detected by indirect immunofluorescence (IIF) on Hep-2 cells (INOVA Diagnostics) following standard protocols (positive titre ≥ 1:80), while smooth muscle antibodies (SMA), liver-kidney microsomal autoantibodies (anti-LKM), PCA, anti-mitochondrial antibodies (AMA) and antibodies against liver cytosol (anti-LC) were detected by IIF on rat liver, kidney and stomach sections as we described elsewhere. Significant titers were considered ≥ 1:80 for SMA and ≥ 1:40 for anti-LKM, PCA and AMA. Anti-neutrophil cytoplasmatic antibodies (ANCA) were detected by IIF on ethanol-fixed granulocytes (INOVA Diagnostics; positive titre ≥ 1:20). All ANCA-reactive samples by IIF were further investigated for the presence of IgG antibodies against proteinase 3 (anti-PR3, INOVA Diagnostics) and myeloperoxidase (anti-MPO, INOVA Diagnostics).

All samples were investigated for the presence of IgG antibodies against double stranded DNA (anti-dsDNA) and IgG anticardiolipin antibodies (anti-CL) using in-house ELISAs following published protocols by us. The specificity, reproducibility and optimal conditions of these assays were determined in extensive preliminary experiments as described. In each assay, the between-day variation of the optical density (A) values was eliminated by running serial dilutions of a positive control (standard curve) on each plate. Briefly, a standard curve was constructed by assaying repeatedly control sera positive for IgG anti-dsDNA and IgG anti-CL in serial dilutions (1:50 to 1:6 400). The A value of the 1:6 400 dilution was arbitrarily chosen as 1 binding unit (BU). The BU values for the test samples were calculated according to this curve. This was accomplished by dividing the A of each sample by the A value, which corresponded to 1 BU for that plate. Finally, the results were expressed as binding index (BI) calculated by dividing the BU of every sample by the mean BU of the healthy controls plus 4SD, multiplied by 100. According to this formula, a BI of 100 was defined as the cut-off point of the assays. The adoption of this stringent cut-off point precluded the possibility of false-positive results.

All subjects consented to participate in the study at the time of interview. The Ethic Committee of Larissa University Hospital approved the study protocol.

**Statistical analysis**

Associations between the presence or absence of autoantibodies and different variables were assessed using the univariate unadjusted $\chi^2$ statistic. Statistical comparisons between means were calculated by one-way analysis of variance.

**RESULTS**

Demographic, epidemiologic, clinical, virologic and histologic characteristics of the patients at baseline are shown in Table 1. The duration of HCV disease was considered the period from the first time of iv drug abuse in iv drug abusers, while in the remaining HCV patients the duration was calculated from the first time of anti-HCV detection. No significant correlation was found between treatment outcome and sex, risk factors for contracting HCV and HCV-viral load. Patients below 45 years old had significantly increased virological ($P = 0.006$) and combined virological and biochemical response rates at the end of follow up ($P = 0.01$), while the presence of genotypes other than 1b or 4 was correlated with a significantly higher virological response rate at the end of treatment ($P<0.03$). In addition, none of the patients with severe fibrosis or cirrhosis achieved sustained biochemical and virological responses ($P<0.05$).

The prevalence of PCA and NOSA in HCV patients studied...
The end of treatment (22/26 patients over 45 years old) was significantly associated with ANA positivity at the end of treatment (51/57; 89.5%), while ANA were found in 54.4%. Age over 45 years was significantly associated with ANA positivity at the end of treatment (22/26 patients over 45 years old vs 18/31 patients under 45 years old, P<0.05).

ANCA were detected commonly in HCV-infected patients (80.7-82.5%). In most cases a diffuse cytoplasmic pattern (cANCA) was recorded. However, due to the absence of anti-PR3 and anti-MPO by ELISAs in all ANCA-positive samples, we considered them as ANCA-negative and they were excluded from further statistical analysis.

In overall, anti-LKM were detected in 4 out of 57 patients (7%) (Tables 2, 3). The only anti-LKM-positive patient who had a sustained biochemical and virological response was that with the highest titer at the entry, which then decreased (end of treatment) and disappeared at the end of follow up (Table 3).

The statistically significant correlations between the presence of PCA and/or NOSA and the response to treatment are shown in Tables 4A-C. The presence of ANA at the entry and at the end of follow up was significantly associated with the reduced rates of sustained biochemical response (Table 4). A combined sustained biochemical and virological response was achieved in a significantly higher proportion of ANA negative patients at the end of follow-up compared to those with ANA reactivity at the same chronic period (Table 5). None of the PCA-positive patients at the entry achieved a sustained virological or sustained biochemical and virological response (Tables 5 and 6).

The treatment outcome was associated with alterations of the titres in some NOSA during the three time-points of investigation (Tables 7, 8 and 9). The decrease of ANA titres was correlated with a significantly increased rate of sustained biochemical (P = 0.005), sustained virological (P = 0.003) and combined biochemical and virological responses (P = 0.001) (Tables 7, 8 and 9).

**Table 1** Characteristics of HCV patients studied

|                                | Non-responders | Relapers | Sustained responders |
|--------------------------------|----------------|----------|---------------------|
|                                | (n = 22)       | (n = 16) | (n = 19)            |
| Sex (M/F)                      | 15/7           | 10/6     | 13/6                |
| Age (Mean/range)               | 48±15          | 50±10    | 37±13               |
| Disease duration (yr)          | 2.4±2.1        | 2.9±3    | 2.5±2.4             |

**Table 2** Prevalence (%) and mean titre of PCA and non-organ specific autoantibodies in HCV patients at three time-points

|                                | Before treatment (n = 57) | End of treatment (n = 57) | End of follow up (n = 57) | P value |
|--------------------------------|--------------------------|---------------------------|---------------------------|---------|
|                                | Pos (%) | Mean titre | Pos (%) | Mean titre | Pos (%) | Mean titre |         |
| ANA                            | 54.4    | 1/188      | 70.2    | 1/194      | 71.9    | 1/171      | NS      |
| SMA                            | 89.5    | 1/127      | 89.5    | 1/135      | 84.2    | 1/118      | NS      |
| Undefined cytoplasmic staining | 12.3    | 1/108      | 19.31   | 1/76       | 14      | 1/248      | NS      |
| undefined PCA                  | 0       | 0          | 0       | 0          |         | NS        |         |
| Anti-LKM                       | 5.3     | 1/133      | 7       | 1/100      | 5.3     | 1/67       | NS      |
| PCA                            | 15.8    | 1/76       | 17.5    | 1/108      | 15.8    | 1/231      | NS      |
| Anti-LC                        | 1.8     | 1/40       | 3.5     | 1/60       | 0       | NS         |         |
| ANCA                           | 80.7    | 1/31       | 80.7    | 1/31       | 82.5    | 1/31       | NS      |
| CANCA                          | 78.9    | 1/28       | 77.2    | 1/30       | 77.2    | 1/28       | NS      |
| PANCA                          | 3.5     | 1/90       | 5.3     | 1/53       | 8.8     | 1/64       | NS      |
| Anti-PR3                       | 0       | 0          | 0       | 0          |         | NS        |         |
| Anti-MPO                       | 0       | 0          | 0       | 0          |         | NS        |         |
| Anti-dsDNA                     | 22.8    | 129 BI     | 24.6    | 135 BI     | 21.1    | 134 BI     | NS      |
| Anti-CL                        | 19.3    | 148 BI     | 29.8    | 138 BI     | 17.5    | 129 BI     | NS      |

Abbreviations are same as in the text. pANCA = ANCA with perinuclear pattern, NS = not statistically significant, n = the number of individuals studied in each group. P values were calculated by one-way analysis of variance for the mean titres and by total χ² for autoantibodies positivity. 1 Means an AMA-like pattern by indirect immunofluorescence on HEp-2 cells, which did not give an AMA pattern on frozen liver, renal and stomach sections and which did not react in specific ELISA for AMA and immunoblot on human liver.
Table 3 Alterations of anti-LKM reactivity in association with the response to therapy in the four anti-HCV positive/anti-LKM-positive patients

| Gender | Genotype | Anti-LKM titre | 1+ | 2+ | 3+ | Response | End of treatment | End of follow-up |
|--------|----------|----------------|-----|----|----|----------|-----------------|-----------------|
| M      | 1b       | 1/120          | 1/40| 0  |    | Responder| Sustained responder |
| F      | 1b       | 1/40           | 1/160| 1/80|    | Responder| Relapser        |
| F      | 2a/c     | 1/40           | 1/40| 1/40|    | Non-responder|                |
| M      | 4        | 0              | 1/160| 1/80|    | Non-responder|                |

Abbreviations are same as in the text. M = male, F = female, 1st, 2nd and 3rd refers to the sample obtained at the entry, at the end of treatment and at the end of follow-up, respectively.

Table 4 Impact of ANA detection on sustained biochemical response of the patients

| Biochemical response at the end of follow up [n (%)] | n | Yes | No | P |
|-----------------------------------------------------|---|-----|----|---|
| ANA entry                                           |   |     |    |   |
| Pos                                                 | 31| 13  | 18 | P = 0.017 |
| Neg                                                 | 26| 20  | 6  |   |
| ANA end of follow up                                 |   |     |    |   |
| Pos                                                 | 41| 20  | 21 | P = 0.037 |
| Neg                                                 | 16| 13  | 3  |   |

Abbreviations are same as in the text. n = the number of individuals in each group, P values were calculated by Fischer’s exact test or χ² where applicable.

Table 5 Impact of PCA and ANA on sustained biochemical and virological response of the patients

| Combined sustained response at the end of follow up [n (%)] | n | Yes | No | P |
|-------------------------------------------------------------|---|-----|----|---|
| PCA entry                                                   |   |     |    |   |
| Pos                                                         | 9 | 0   | 9  | P = 0.022 |
| Neg                                                         | 48| 19  | 29 |   |
| ANA end of follow up                                        |   |     |    |   |
| Pos                                                         | 41| 10  | 31 | P = 0.048 |
| Neg                                                         | 16| 9   | 7  |   |

Abbreviations are same as in the text. n = the number of individuals in each group, P values were calculated by Fischer’s exact test or χ² where applicable.

Table 6 Impact of PCA on sustained virological response of the patients

| Virological response at the end of follow up [n (%)] | n | Yes | No | P |
|-----------------------------------------------------|---|-----|----|---|
| PCA entry                                           |   |     |    |   |
| Pos                                                 | 9 | 0   | 9  | P = 0.02 |
| Neg                                                 | 48| 20  | 28 |   |

Abbreviations are same as in the text. n = the number of individuals in each group, P values were calculated by Fischer’s exact test or χ² where applicable.

Table 7 Impact of ANA and SMA alterations at the three time-points of investigation on the sustained virological response of the patients

| Virological response at the end of follow up [n (%)] | n | Yes | No | P |
|-----------------------------------------------------|---|-----|----|---|
| Alteration of ANA titres                            |   |     |    |   |
| Increase                                            | 20| 8   | 12 | P = 0.02 |
| Decrease                                            | 13| 8   | 5  |   |
| Constant                                            | 24| 4   | 20 |   |
| Alteration of SMA titres                            |   |     |    |   |
| Increase                                            | 14| 3   | 11 | P = 0.003 |
| Decrease                                            | 18| 12  | 6  |   |
| Constant                                            | 25| 5   | 20 |   |

Abbreviations are same as in the text. n = the number of individuals in each group of patients, Alterations of autoantibodies titres are referred to the period from entry to end of follow-up, P values were calculated by total χ².

Table 8 Impact of ANA and SMA alterations at the three time-points of investigation on the sustained combined biochemical and virological response of the patients

| Combined sustained response at the end of follow up [n (%)] | n | Yes | No | P |
|-------------------------------------------------------------|---|-----|----|---|
| Alteration of ANA titres                                    |   |     |    |   |
| Increase                                                    | 20| 7   | 13 | P = 0.02 |
| Decrease                                                    | 13| 8   | 5  |   |
| Constant                                                    | 24| 4   | 20 |   |
| Alteration of SMA titres                                    |   |     |    |   |
| Increase                                                    | 14| 2   | 12 | P = 0.001 |
| Decrease                                                    | 18| 12  | 6  |   |
| Constant                                                    | 25| 5   | 20 |   |

Abbreviations are same as in the text. n = the number of individuals in each group of patients, Alterations of autoantibodies titres are referred to the period from entry to end of follow-up, P values were calculated by total χ².

Table 9 Impact of SMA alterations at the tree time-points of investigation on the sustained biochemical response of the patients

| Biochemical response at the end of follow up [n (%)] | n | Yes | No | P |
|-----------------------------------------------------|---|-----|----|---|
| Alteration of SMA titres                            |   |     |    |   |
| Increase                                            | 14| 7   | 7  | P = 0.005 |
| Decrease                                            | 18| 16  | 2  |   |
| Constant                                            | 25| 10  | 15 |   |

Abbreviations are same as in the text. n = the number of individuals in each group of patients, Alterations of autoantibodies titres are referred to the period from entry to end of follow-up, P values were calculated by total χ².

DISCUSSION

We demonstrated that the majority of HCV patients had circulating NOSA while a significant proportion had also PCA. Several organ and NOSA has already been associated with HCV infection both in adults and children[6,16,22-28]. So far however, very few studies have been strictly designed to investigate the alterations of these autoantibodies and their impact on the treatment outcome after a course of IFN-α. In addition, some of the previous data regarding the variation and influence of NOSA on the response to IFN-α were referred to the childhood[6,25] and not to the adult population.

Our study confirmed that PCA and NOSA were frequently detected in HCV patients. Similarly to previous reports by Gregorio et al[6,36], these autoantibodies appeared to be a part of the natural course of chronic hepatitis C, since their prevalence and titre were unaffected by IFN-α, but in this study a relatively small number of patients were followed up (7 patients only).

Interestingly however, we found that the presence and the titre alterations in some of these autoantibodies during the follow-up period had an effect on the treatment response. In particular, the presence of ANA at the entry and the end of

...
follow up, as well as the detection of PCA at the entry were correlated with a worse response. Additionally, the decrease of ANA and SMA titres from the entry to the end of follow up was associated with a better outcome after IFN-α therapy. Our findings are in accordance with only two very recent studies by Muratori et al.[23] and Wasmuth et al.[29], which investigated the impact of NOSA on IFN-α with or without combination with ribavirin treatment in HCV-infected children and adults. However, other studies have shown no relation of organ and NOSA with response to treatment[6,23,24,27,37,38].

Apart from treatment outcome, the clinical significance of PCA and NOSA in our series of patients remains obscure. Among several autoantibodies investigated, only ANA were associated with older ages, which is in agreement with the findings of Squadrito et al.[14], but in contrast with other studies[22,39]. In addition, similarly with a recent study by Strofolini et al.[39], we were not able to show any correlation between the positivity of autoantibodies and liver damage. In contrast, other reports supported that continuous hepatocellular damage due to HCV might be an essential step for the production of autoantibodies[8,13,38].

Under this context and in view of the growing evidence for molecular mimicry as a mechanism of autoimmunity, a recent elegant study by Gregorio et al.[40] has shown that ANA and SMA in chronic HCV-infection may arise as a consequence of cross-reactive immune responses to HCV and host smooth muscle/nuclear antigens. The latter speculation could support, at least in part, our findings where a favorable biochemical and virological response was associated with a decline of ANA and SMA titres (the lower the viral load, the lower the cross-reactive immune response with host antigens).

We were not able to show any significant alterations of PCA during therapy, which is in contrast with recent observations by Fabbri et al.[15]. These researchers demonstrated a statistically significant increase of patients positive for PCA during IFN-α treatment, which was associated with the development of autoimmune gastritis and autoimmune thyroiditis[15]. ANCA were considered to be negative because we did not find reactivity against MPO or PR-3 by specific ELISAs. This finding is similar with that reported previously by our group[41] and others[42]. However, a recent study in HCV patients by Wu et al.[42] reported a high prevalence of CANA by identifying PR-3 as their major target autoantigen.

The prevalence of anti-LKM in our patients is comparable with previous works from our group and others[5,6,8,11,24,25]. Only one of our HCV+/anti-LKM+ patients succeeded a sustained response. Interestingly, this patient had the highest titre at the entry among the anti-LKM positive patients and was infected with genotype 1b. Nevertheless, the progressive decline of anti-LKM titre up to disappearance at the end of follow up was associated with a combined sustained biochemical and virological response. The disappearance of this antibody in virological response between the virus and cytochrome P450 2D6 (CYP2D6)[43]. Additional supports to this hypothesis emerged from recent studies by Kerkar et al.[44] and Bogdanos et al.[45]. In the first study the authors were able to show cross-reactivity between the immunodominant epitope 193-212 of CYP2D6 and homologies of two unrelated viruses (HCV 2977-2996 and CMV 121-140)[44]. In the second study the investigators for the first time gave experimental support to the notion that molecular similarities between CYP2D6, HCV and herpes simplex virus could result in anti-LKM production via a cross-reactive response[45]. Although occasionally IFN-α might unmask or provoke autoimmune hepatic reactions and even “true” autoimmune hepatitis in HCV-treated patients[24,46,47], the response rate to IFN-α was in general the same both in anti-LKM-positive and anti-LKM-negative HCV patients. This was also the case in our patients.

In conclusion, PCA and NOSA, including anti-LKM, are commonly found in antiviral HCV patients. Although serospecificity for these autoantibodies should not affect the decision to treat HCV patients, the presence of some of them such as ANA, PCA and SMA before treatment or their increase during IFN-α therapy may predict a worse response, suggesting the need for a more intensive follow up during treatment of HCV patients positive for these autoantibodies. Two very recent studies, one in children and the other in adult population with hepatitis C, could enhance our findings since both of them have demonstrated a lower benefit from IFN-α therapy among NOSA-positive/HCV-positive subjects[25,28]. Future prospective studies are needed to uncover the full spectrum of these associations and to provide new insights into their operating mechanisms.

REFERENCES

1. Tsianos EV, Dalekos GN, Merkouropoulos MH, Tsatsoulis A, Segertidis KI. Frequency of thyroid dysfunction after recombinant alpha-interferon therapy in Greek patients with chronic active hepatitis. Eur J Gastroenterol Hepatol 1994; 6: 547-551
2. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol 2000; 12: 391-398
3. Christodoulou DK, Dalekos GN, Merkouropoulos MH, Kistis KG, Georgiatis G, Zervou E, Zachou K, Tsianos EV. Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice. Eur J Intern Med 2001; 12: 435-441
4. Dalekos GN, Manouselakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. Eur J Clin Invest 1993; 23: 219-225
5. Bortoloti F, Vairo P, Balli F, Giacchino R, Crivellaro C, Barbera C, Catalata M, Muratori L, Pontissos P, Nebbia G, Zancan G, Zanck L, Bertolini A, Alberti A, Bianchi F. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996; 25: 614-620
6. Gregorio GV, Pensati P, Iorio R, Vegnente A, Miedi-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998; 112: 471-476
7. Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP. Epitope mapping of cytochrome P4502D6 autoantigens in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30: 366-373
8. Lentzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45: 435-441
9. Dalekos GN, Kistis KG, Boubra DS, Vouliardi P, Zervou EK, Drosos AA, Tsianos EV. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74
10. Dalekos GN, Zachou K, Liakos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001; 3: 277-285
11. Dalekos GN, Makri E, Loges S, Obermayer-Straub P, Zachou K, Tsikrikas T, Schmidt E, Papadomou G, Manns MP. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece. Eur J Gastroenterol Hepatol 2002; 14: 35-42
12. Wu YY, Hsu TC, Chen TY, Liu TC, Liu GY, Lee YJ, Tsay GJ. Proteinase 3 and dihydroxyalapoide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 2002; 128: 347-352
13. Muratori P, Muratori L, Strofili T, Pappas G, Terlizzi P, Ferrari R, Loffreda S, Cassani F, Rapicetta M, Guadagnino V, Bianchi FR, Lentzi M. Prevalence of non-organ-specific autoantibodies in HCV-infected subjects in the general population. Clin Exp Immunol 2003; 131: 118-121
14. Squadrito G, Previti M, Lentzi M, Le Rose EP, Caccamo G, Restuccia T, Di Cesare E, Pollicino T, Raimondo G. High prevalence of non-
organ-specific autoantibodies in hepatitis C virus-infected cirrhotic patients from southern Italy. Dig Dis Sci 2003; 48: 349-353
15 Fabbri C, Jaboli MF, Giovannelli S, Azzaroli F, Pezzoli A, Accogli E, Liva S, Nigo G, Miracolo A, Festi D, Cecchilla A, Montagnani M, Roda E, Mazzella G. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003; 9: 1487-1490
16 Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Ragun G, Piette JC. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l’Hepatite C. Medicine (Baltimore) 2000; 79: 47-56
17 McHutchon JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventionsal Therapy Group. N Engl J Med 1998; 339: 1485-1492
18 Manns MP, McHutchon JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury L, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: randomised trial. Lancet 2001; 358: 958-965
19 Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
20 Fattovich G, Giustina G, Favaro S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47
21 Dalekos GN, Christodoulou D, Kistsis KG, Zervou EK, Hatzis J, Tsiason EV. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. J Gastroenterol Hepatol 1998; 10: 933-939
22 Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, Bonkovsky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613-619
23 Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K, Tanaka M, Yoshihara H. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the interferon therapy. Sand J Gastroenterol 1996; 31: 716-722
24 Cassani F, Cataleta M, Valentinii P, Muratori P, Giosfra E, Francesconi R, Muratori L, Lenzi M, Bianch G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26: 561-566
25 Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB, Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37: 1320-1326
26 Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P. A study of autoimmune markers in hepatitis C infection. Indian J Med Res 2001; 113: 170-174
27 Wada M, Kang KB, Kinugasa A, Shimani S, Sawada K, Nishigami T, Shimoyama T. Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997; 36: 248-254
28 Wasmuth HE, Stolte C, Geier A, Dietrich CG, Hartung C, Lorenzen J, Matern S, Lammert F. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4: 4-12
29 Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselas N, Georgiadiou SP, Tsiason EV, Dalekos GN. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-168
30 Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancoada EL, Champion RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcoat J, Homborg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfeld KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
31 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numeri- cal scoring system for assessing histological activity in asymptot- ic chronic active hepatitis. Hepatology 1981; 1: 431-435
32 Georgiadou SP, Zachou K, Rigopoulos E, Liaskos C, Mina P, Gerovasili F, Makri E, Dalekos GN. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004; 11: 358-365
33 Simmonds P, McIntosh F, Yap PL,Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC. Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993; 74 (Pt 4): 661-668
34 Dalekos GN, Obermayer-Straub P, Bartels M, Maeda T, Kayser A, Braun S, Loges S, Schmidt E, Gershwin ME, Manns MP. Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol 2003; 39: 800-806
35 Dalekos GN, Goussous M, Tsiason EV, Moutsopoulos HM. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibod- ies in patients with ulcerative colitis. Gut 1993; 34: 658-664
36 Gregorio GV, Jones H, Choudhuri K, Vengnente A, Bortolotti F, Mieli-Vergani G, Vergani D. Autoantibody prevalence in chronic hepatitis B virus infection: effect in interferon alfa. Hepatology 1996; 24: 520-529
37 Todros L, Saracco G, Durazzo M, Abate ML, Tousoz G, Scaglione L, Verme G, Rizzetto M. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22: 1374-1378
38 Massard J, Johonet C, Bedossa P, Poynard T, Buffet C, Di Martino V. Impact of hepatitis C-associated autoantibodies (AAbs) on the liver pathology and the response to antiviral therapy [abstract]. J Hepatol 2003; 38 (Suppl 2): 155
39 Stroffolini T, Colloredo G, Gaeta GB, Sonzogni A, Angeletti S, Marigiani M, Pasquale G, Venezia G, Craxi A, Almasio P. Does an ‘autoimmune’ profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004; 11: 257-262
40 Gregorio GV, Choudhuri K, Ma Y, Pensati P, Iorio R, Grant P, Garson J, Bogdanos DP, Vengenate A, Mieli-Vergani G, Vergani D. Immunity between the hepatitis C virus polypeptide and anti- gen targets of smooth muscle antibodies in liver-kidney microsomal autoantibody type 1-positive hepatitis C virus infection. Clin Exp Immunol 2003; 134: 403-414
41 Dalekos GN, Tsiason EV. Neutral and autoantibodies to the protein in chronic viral hepatitis. J Hepatol 1994; 20: 561
42 Rozendaal C, de Jong MA, van den Berg AP, van Wijk RT, Limburg PC, Kallenborg CG. Clinical significance of anti-neu- trophil cytoplasmatic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 33: 734-741
43 Muratori L, Parola M, Rippli A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, Bianchi FB. Liver/ kidney microsomal antibody type 1 targets CYP2D6 on hepa- tocyte plasma membrane. Gut 2000; 46: 553-561
44 Kerkar N, Choudhuri K, Ma Y, Mahmood A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6 (193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 2003; 170: 1481-1489
45 Bogdanos DP, Lenzi M, Okamoto M, Rigopoulos EL, Muratori P, Ma Y, Muratori L, Tsantoulas D, Mieli-Vergani G, Bianchi FB, Vergani D. Multiple viral/self immunological cross-react- ivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol 2004; 17: 83-92

Edited by Wang XL